RATIONALE: PEG-interferon alfa-2b may interfere with the growth of tumor cells. It may also stop the growth of tumor cells by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well PEG-interferon alfa-2b works in treating patients with unresectable plexiform neurofibromas associated with neurofibromatosis type 1.
Find Clinical Trials
To find clinical trials that focus on targeted therapies, use the pulldown menus below or enter a term in the search box.
Request a Consultation
To schedule a consultation with an oncologist at Dana-Farber/Brigham and Women's Cancer Center, please call one of our experienced appointment coordinators.
